New antibody shot could zap stubborn acne
NCT ID NCT07449156
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This early-stage study tests a new drug called HB0043 in 21 adults with moderate to severe acne. The drug is a bispecific antibody that targets two inflammatory pathways (IL-17A and IL-36R) thought to drive acne. The main goal is to see if it safely reduces acne lesions and improves skin appearance compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University,
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.